How do new EU rules affect medicine supply to Ireland and Malta?

Question

Accepted Answer

New EU Rules Propose Easing Medicine Movement to Northern Ireland, Cyprus, Ireland, and Malta

The European Commission has put forward legal amendments intended to facilitate the movement of medicines from Great Britain to Northern Ireland, as well as to Cyprus, Ireland, and Malta. These proposed changes aim to prevent potential supply disruptions stemming from the Brexit withdrawal agreement. Specifically, the EU executive has suggested an exemption that would permit compliance and testing for generic medicines to be conducted on the British mainland, with the same packaging permissible for use in Northern Ireland.
Exemption for Generic Medicine Compliance and Testing

Under the proposed changes, the European Commission is seeking to allow compliance and testing procedures for generic medicines to take place in Great Britain. This exemption is designed to circumvent regulatory hurdles that could have otherwise forced companies to relocate these facilities to the EU or Northern Ireland. Such a move could have been financially prohibitive, potentially leading some businesses to cease supplying essential medicines to Northern Ireland and exacerbating existing trade challenges.
Accelerated Marketing Authorisation for New Drugs

A further proposed amendment would permit the marketing of new drugs in Northern Ireland subsequent to their authorisation by the British medicines regulator. This would allow for the faster availability of novel treatments, such as those for cancer, in Northern Ireland even before formal approval by the European Medicines Agency. This measure aims to streamline access to innovative pharmaceuticals for patients in the region.
Broader Impact on EU Member States

While the primary focus of the proposed changes is on Northern Ireland, the modifications are also set to impact the supply of medicines to other EU member states, specifically Cyprus, Ireland, and Malta. The exact nature of these effects on the medicine supply chains, regulatory processes, and availability in Ireland and Malta is not detailed in the provided information. The proposed changes require the approval of the European Parliament and EU governments in 2022.

Reading history

Hide →

This history is cleared when the page is closed.

How do new EU rules affect medicine supply to Ireland and Malta?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends